Immunopathology of Loeys-Dietz Syndrome

Status: Completed
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Loeys-Dietz syndrome (LDS) is a rare vascular genetic disorder (estimated prevalence 1/25,000-1/100,000) due primarily to mutations in the Transforming growth factor beta (TGF-β) cytokine receptor 1 and 2 genes. In addition to a common vascular phenotype with Marfan syndrome (dilatation of the ascending aorta, arachnodactyly, lens dislocation), patients present specific malformations (bifid uvula, hypertelorism, tortuous arteries) and immuno-allergic manifestations (asthma, eczema, food allergy, eosinophilic esophagitis, chronic inflammatory bowel disease). Pathophysiologically, LDS appears to be associated with hyperactivation of the intracellular TGF-β signaling pathway in a manner similar to Marfan syndrome, as evidenced by increased intracellular phosphorylated Smad2/3 (pSmad2/3) in lymphocytes. The immuno-allergic complications appear paradoxical because of the major immunosuppressive role of this cytokine on lymphoid and myeloid immune lineages. The biological description of immunological abnormalities associated with LDS is based on a single 2013 study that found increased regulatory T (Treg) and Th2 lymphocyte polarizations, as well as increased circulating eosinophil and total IgE levels. In order to better understand the underlying mechanisms, the investigators propose to perform a descriptive clinical-biological study to identify and study the immune subpopulations most impacted by the causative mutations of LDS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 86
Healthy Volunteers: t
View:

⁃ For patients with Loeys-Dietz syndrome:

• Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation known to be pathogenic to patients.

• Free, informed and signed consent from the patient or both parents or legal guardians for minor patients.

• Patient affiliated to a social security system or similar.

⁃ For healthy volunteers:

• Subjects aged ≥ 5 years.

• Free, informed and signed consent of the witness, or if applicable of both parents or legal representatives for minors.

• Patient affiliated to a social security system or similar.

Locations
Other Locations
France
Hôpital Femme-Mère-Enfant / Centre de Compétences pour le syndrome de Marfan et apparentés
Bron
Time Frame
Start Date: 2022-10-17
Completion Date: 2023-06-07
Participants
Target number of participants: 60
Treatments
Other: Loeys-Dietz syndrome
Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation.
Other: Healthy Group
Subjects aged ≥ 5 years.
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.